Mortality and other adverse outcomes in patients with type 2 diabetes mellitus admitted for COVID-19 in association with glucose-lowering drugs: a nationwide cohort study

by Luis M. Pérez-Belmonte, José David Torres-Peña, María D. López-Carmona, M. Mar. Ayala-Gutiérrez, Francisco Fuentes-Jiménez, Lucía Jorge Huerta, Jaime Alonso Muñoz, Manuel Rubio-Rivas, Manel Madrazo, Marcos Guzmán Garcia, Beatriz Vicente Montes, Joaquim Fernández Sola, Javier Ena, Ruth Gonzalez Ferrer, Carmen Mella Pérez, Carlos Jorge Ripper, Jose Javier Napal Lecumberri, Iris El Attar Acedo, Susana Plaza Canteli, Sara Fuente Cosío, Francisco Amorós Martínez, Begoña Cortés Rodríguez, Pablo Pérez-Martínez, José Manuel Ramos-Rincón, Ricardo Gómez-Huelgas, for the SEMI-COVID-19 Network
Published 2020-11-01